| Bioactivity | EC-17 (disodium salt) is a folate receptor alpha (FRα) targeting contrast agent with fluorescent properties in the visible light spectrum. The peak excitation and emission wavelengths of EC-17 are 470/520 nm. |
| Target | Folate receptor alpha |
| Invitro | EC-17 contains the fluorescein fluorochrome and has a spectral wavelength of 490–530 nm. EC-17 is synthesized by a folate (vitamin B9) and fluorescein isothiocyanate (FITC) conjugated through an ethylenediamine spacer to produce folate-FITC, with a molecular weight of 917 kDa. FITC is a derivative of fluorescein functionalized with an isothiocyanate reactive group. The folate-FITC conjugate forms a negatively charged fluorescent molecule that specifically targets cell-surface FRα and is subsequently internalized into the cytoplasm. The signal-to-background ratio (SBR) of EC-17 for HeLa cells range from 0.97 to 7.32 depending on the molarity and concentration of cancer cells[1]. |
| In Vivo | The mean fluorescence signal from the animals injected with EC-17 to be 42,234 ± 12,234 au[1]. Fluorescence microscopy for folate-FITC shows a strong signal in all malignant tumors with FR-α expression and no signal in FR-α–negative malignant or benign lesions[2]. |
| Name | EC-17 disodium salt |
| CAS | 910661-33-5 |
| Formula | C42H34N10Na2O10S |
| Molar Mass | 916.82 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | -20°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
| Reference | [1]. Tummers QR, et al. Intraoperative imaging of folate receptor alpha positive ovarian and breast cancer using the tumor specific agent EC17. Oncotarget. 2016 May 31;7(22):32144-55. |